GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$38.84 USD
+0.38 (0.99%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $38.84 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GSK 38.84 +0.38(0.99%)
Will GSK be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GSK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GSK
GSK Buys Flu, COVID mRNA Jab Rights From Partner CureVac
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
GSK: What are Zacks experts saying now?
Zacks Private Portfolio Services
CHMP Endorses Moderna's (MRNA) mRNA-based RSV Vaccine
CDC Narrows Age Recommendation for Use of RSV Vaccine
Moderna (MRNA) Shares Decline on RSV Vaccine Efficacy Data
Other News for GSK
UK dividends calendar
UK dividends calendar - next 7 days
GLOBAL BROKER RATINGS: Exane raises Lloyds, DZ 'hold' on Givaudan
LONDON BROKER RATINGS: Jefferies cuts Softcat to 'underperform'
UK dividends calendar - next 7 days